Trials / Not Yet Recruiting
Not Yet RecruitingNCT06941480
A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate
Characterizing the Theranostic Potential of DLL3-targeting Agents in High-grade Neuroendocrine Carcinomas of the Lung and Prostate
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether 177Lu-DTPA-SC16.56 is a safe treatment for people with small-cell lung cancer or neuroendocrine prostate cancer
Conditions
- Neuroendocrine Tumor of the Lung
- Neuroendocrine Carcinoma of Lung
- Neuroendocrine Carcinoma
- Neuroendocrine Carcinoma of Prostate
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | PET/CT | Participants will undergo 89Zr-DFO-SC16.56 Ab PET/CT |
| BIOLOGICAL | 177Lu-DTPA-SC16.56 | 177Lu-DTPA-SC16.56, to be administered within 2 weeks of the PET/CT |
Timeline
- Start date
- 2026-06-01
- Primary completion
- 2030-05-01
- Completion
- 2030-05-01
- First posted
- 2025-04-23
- Last updated
- 2026-04-14
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06941480. Inclusion in this directory is not an endorsement.